GPCR240920C70000
- 0.45
- 0.000.00%
Structure Therapeutics Newsroom
Press Release: Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
Express News | Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.d., Ph.d. to Chief Medical Officer and Appointment of Ashley Hall, J.d. as Chief Development Officer
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
JMP Securities analyst Jonathan Wolleben maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $86.According to TipRanks data, the analyst has a success
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Jefferies analyst Roger Song maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 32.4%
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler
Structure Therapeutics Inc. (GPCR): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Express News | Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Press Release: Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Deutsche Bank has upgraded its rating on Eli Lilly and Co (LLY.US) from "hold" to "buy" with a target price increase from $725 to $1025.